Multiple myeloma is a blood cancer of plasma cells in the bone marrow, diagnosed in about 35,000 Americans each year. Treatment has transformed over two decades from single-agent chemotherapy to combinations of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and stem cell transplant. Many people now live years with the disease, though it remains incurable for most.
What's actually going on in research
Trials are testing CAR-T cell therapies, bispecific antibodies that redirect immune cells to kill myeloma, and combinations that aim to deepen remissions or delay relapse. Researchers are also studying minimal residual disease testing to guide treatment decisions, and new drugs for high-risk genetic subtypes that respond poorly to standard therapy.
CAR-T cell therapy
Two CAR-T therapies targeting BCMA — idecabtagene vicleucel and ciltacabtagene autoleucel — are FDA-approved for relapsed myeloma. Trials are now testing them earlier in treatment and in combination with other drugs.
Bispecific antibodies
These drugs link a myeloma cell to a T cell, forcing the immune system to attack the cancer. Teclistamab and elranatamab are FDA-approved, and trials are testing other targets and earlier use.
High-risk disease
About 15 percent of myeloma has genetic features that predict poor outcomes with standard treatment. Studies are testing whether more aggressive or novel regimens can overcome this resistance.
What to know before you search
Eligibility typically depends on how many prior treatments you've had, your genetic risk profile, kidney and heart function, and whether you've received prior CAR-T or stem cell transplant.
What types of trials are currently open
- CAR-T trials — Testing CAR-T cell therapy at different treatment stages and in combination with drugs that may help it work better or last longer.
- Bispecific antibody trials — Testing antibodies that redirect immune cells to attack myeloma, often as single drugs or combined with standard treatments.
- Combination trials — Testing whether adding a new drug to standard treatment improves remission depth or delays relapse.
- Maintenance trials — Testing drugs given after initial treatment to keep the disease under control longer.
- Minimal residual disease trials — Studies that use sensitive tests to detect tiny amounts of remaining myeloma and guide decisions about continuing or stopping treatment.
Recently added Multiple Myeloma trials
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma. The study will be conducted in a population of male and female subjects aged 18 years and older, with confirmed symptomatic multiple myeloma with measurable disease, who have received one prior line of therapy that included a proteasome inhibitor and lenalidomide and were refractory to lenalidomide, or who have received two or three prior lines of therapy that included a proteasome inhibitor and lenalidomide, with disease progression during or after the last line of therapy.
Receive an experimental immune cell therapy for multiple myeloma
This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the treatment of relapsed or refractory multiple myeloma.
Find Multiple Myeloma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.